About This Webinar  Cell and gene therapy programs require rigorous quality oversight from early development through commercial manufacturing. Poorly defined quality agreements, unclear role delineation, or reactive risk management can introduce compliance gaps and delay technology transfer. In this discussion, quality leaders share practical frameworks for structuring sponsor–CDMO quality agreements that evolve with program maturity. … Continued